Abstract | BACKGROUND: METHODS: We report the results of the extension from 2 to 4 years of a randomized, placebo-controlled trial of HRT in postmenopausal women with primary hyperparathyroidism. Of 23 postmenopausal women with primary hyperparathyroidism, 11 received active HRT with conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 5 mg/d, and 12 received placebo. Bone mineral density was measured throughout the skeleton at 6-month intervals using dual-energy x-ray absorptiometry in these women and in 50 normocalcemic age-matched control subjects. None of the 23 patients withdrew during the extension period. RESULTS: Changes in bone mineral density were more positive in those taking HRT than placebo, with the between-group differences at 4 years being 4.6% in the total body, 7.5% in the lumbar spine, 7.4% in the femoral neck, 8.2% in the femoral trochanter, 6.8% in the legs, and 7.0% in the forearm (P<.01). At skeletal sites composed predominantly of cortical bone, there was a progressive divergence of the 2 groups. Biochemical markers of bone turnover remained lower throughout the study in women taking HRT. When rates of bone loss were compared between the placebo group and healthy women of comparable age, bone loss tended to be more marked throughout the skeleton in women with hyperparathyroidism, but only in the total body and its legs subregion was this difference significant. CONCLUSIONS:
|
Authors | B J Orr-Walker, M C Evans, J M Clearwater, A Horne, A B Grey, I R Reid |
Journal | Archives of internal medicine
(Arch Intern Med)
Vol. 160
Issue 14
Pg. 2161-6
(Jul 24 2000)
ISSN: 0003-9926 [Print] United States |
PMID | 10904459
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Estrogens, Conjugated (USP)
- Progesterone Congeners
- Medroxyprogesterone Acetate
|
Topics |
- Absorptiometry, Photon
- Aged
- Body Mass Index
- Bone Density
(drug effects)
- Drug Therapy, Combination
- Estrogens, Conjugated (USP)
(therapeutic use)
- Female
- Follow-Up Studies
- Hormone Replacement Therapy
- Humans
- Hyperparathyroidism
(complications, metabolism)
- Medroxyprogesterone Acetate
(therapeutic use)
- Osteoporosis, Postmenopausal
(etiology, metabolism, prevention & control)
- Postmenopause
(drug effects, metabolism)
- Progesterone Congeners
(therapeutic use)
- Treatment Outcome
|